Malaysia
Search
Sign In
Change Password
Points
Sign Out
Top Medical News
About two in three men with prostate cancer are at increased cardiovascular (CV) risk, suggests a recent study. A positive association exists between a plan to use androgen deprivation therapy and baseline CV risk factors, but such link is explained by confounding factors.
Excessive levels of uric acid in the blood are a risk factor for hypertension, independent of alcohol consumption, a study has found.
Obesity status appears to contribute to the association between dietary calcium intake and incident cardiovascular disease (CVD), suggests a recent study.
Small dense low-density lipoprotein cholesterol (sd-LDL-C) is a strong predictor of stroke severity and intracranial artery calcification (IAC) in patients with acute ischaemic stroke (AIS), a study has shown.
Angiotensin II receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors (ACEIs) show superiority over other blood pressure (BP)-lowering medications in terms of reducing high-sensitivity C-reactive protein (hs-CRP) and procalcitonin levels in COVID-19 patients with pre-existing hypertension, as shown in a recent study.
Continuation of ticagrelor monotherapy results in a lower incidence of bleeding without increasing the risk of ischaemic events than that of the combined ticagrelor plus aspirin therapy among patients undergoing percutaneous coronary intervention (PCI) who initially completed 3 months of ticagrelor plus aspirin, according to a study.
Elevated blood pressure (BP) variation appears to contribute to a wide range of subclinical brain structural changes, including magnetic resonance imaging (MRI) markers of cerebral small vessel disease, smaller brain tissue volumes and worse white matter microstructural integrity, suggests a recent study.
Special Reports
This second issue revisits the impact EMPA-REG OUTCOME had on clinical
practice and helps readers discover how it gives life back to patients
through its cardiovascular indication. Learn how it was approved and the
possible
mechanisms for its cardiovascular benefits.
Dropping aspirin after 3 months of dual therapy with ticagrelor reduced bleeding in patients with diabetes who have undergone PCI* vs taking both agents for 1 year, the TWILIGHT-DM** study has shown, consistent with benefits seen in TWILIGHT for other high-risk patients.
Among patients undergoing complex percutaneous coronary intervention (PCI) who completed 3 months of dual antiplatelet therapy (DAPT) comprising aspirin and the potent P2Y12-receptor inhibitor ticagrelor, aspirin withdrawal led to fewer bleeding episodes without increasing the risk of ischaemic events compared with continued DAPT, according to data from the TWILIGHT-COMPLEX* subanalysis presented at ACC.20/WCC Virtual.
Taking ticagrelor alone — and dropping aspirin — after 3 months of DAPT* post-PCI** significantly reduced bleeding events without increasing the risk of ischaemic adverse events compared with continuing a DAPT of ticagrelor plus aspirin, the TICO*** trial has shown.
This is the first issue in a series of five
articles celebrating the fifth anniversary of EMPA-REG OUTCOME’s trial data
release. This issue brings insight to the trial’s background, study design and
key results.
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Hypertension (HPT) is defined as a persistent elevation of systolic blood pressure (BP) of 140 mmHg or greater and/or diastolic BP of 90 mmHg or greater, taken at least twice ontwo separate occasions. The most recent National Health and Morbidity Survey (NHMS) 2015 that focuses on noncommunicable diseases showed that among adults aged 18 years and older, there was an increase in the prevalence of HPT from 33.6% in 2011 to 35.3%. While the proportion of patients with HPT who have attained good BP control has increased from 34.7% in 2011 to 37.4%, the awareness of the condition among patients remains poor. The prevalence of undiagnosed HPT remains high; hence, it is recommended that every adult aged 18 years and older to check their BP at least once annually, and more frequently in those with risk factors (eg, family history, obese).
Conference Reports
Dropping aspirin after 3 months of dual therapy with ticagrelor reduced bleeding in patients with diabetes who have undergone PCI* vs taking both agents for 1 year, the TWILIGHT-DM** study has shown, consistent with benefits seen in TWILIGHT for other high-risk patients.
Among patients undergoing complex percutaneous coronary intervention (PCI) who completed 3 months of dual antiplatelet therapy (DAPT) comprising aspirin and the potent P2Y12-receptor inhibitor ticagrelor, aspirin withdrawal led to fewer bleeding episodes without increasing the risk of ischaemic events compared with continued DAPT, according to data from the TWILIGHT-COMPLEX* subanalysis presented at ACC.20/WCC Virtual.
Taking ticagrelor alone — and dropping aspirin — after 3 months of DAPT* post-PCI** significantly reduced bleeding events without increasing the risk of ischaemic adverse events compared with continuing a DAPT of ticagrelor plus aspirin, the TICO*** trial has shown.
Patients with cancer who develop venous thromboembolism (VTE) could reduce their risk of VTE recurrence with the direct oral anticoagulant (DOAC) apixaban, which demonstrated noninferiority to subcutaneous dalteparin in the Caravaggio* trial.
Rivaroxaban reduced venous thromboembolism (VTE) risk without increasing bleeding compared with enoxaparin in patients who underwent lower limb nonmajor orthopaedic surgery, the PRONOMOS* trial showed.
Transcatheter aortic valve replacement (TAVR) in patients with bicuspid aortic stenosis who are at low surgical risk appears to be safe with low rates of death or disabling stroke at 30 days, according to a study presented at the ACC.20/WCC Virtual Meeting.
Two US-based prospective studies presented at the recent EPI Scientific Sessions 2020 suggested that replacing animal-based foods with plant-based ones could reduce mortality and cardiovascular disease (CVD) risk.
Multimedia
